I finally found out from Genentech that the only availability in this trial is for breast cancer. It was a multi-cancer trial with slots for different diseases. Best to stay in contact with those in UK and Europe/Australia who are running trials to see what is recruiting. They are the horse’s mouth and know best what is coming along. I do think approvals in US of PD1’s will transcribe to global but there is the difficulty of cost and approval by regulatory there as barriers.
I’m talking about the PDL trial by Genentech *)owned by Roche, NCT01375842. It only has openings for breast cancer and they must be triple negative patients. The one you mention is randomized with IPI and interferon. The one I hoped for is PDL alone.
Viewing 3 posts - 1 through 3 (of 3 total)
The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.